Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M, Oing C, Dieing A, Gauler T, Oechsle K, Lorch A, Hentrich M, Kopp HG, Bokemeyer C, Honecker F. Fenner M, et al. Among authors: bokemeyer c. J Cancer Res Clin Oncol. 2019 Mar;145(3):717-723. doi: 10.1007/s00432-018-2752-z. Epub 2018 Sep 19. J Cancer Res Clin Oncol. 2019. PMID: 30232558 Clinical Trial.
Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.
Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H, Manegold C, Räth U, Siegert W, et al. Harstrick A, et al. Among authors: bokemeyer c. J Cancer Res Clin Oncol. 1991;117 Suppl 4:S198-202. doi: 10.1007/BF01613227. J Cancer Res Clin Oncol. 1991. PMID: 1665492 Clinical Trial.
960 results